Literature DB >> 2035917

Effects of topical administration of timolol maleate on intraocular pressure and pupil size in dogs.

D A Wilkie1, C A Latimer.   

Abstract

Effects of topical administration of a single dose of timolol maleate on intraocular pressure (IOP) and pupil diameter were evaluated in normotensive eyes of 11 clinically normal dogs over 12 hours (7:00 AM to 7:00 PM). Mean (+/- SEM) normal IOP was 15.5 (+/- 1.1) mm of Hg and diurnal fluctuation was observed, with the highest IOP seen in the morning. Mean normal pupil diameter was 8.5 (+/- 0.3) mm. Topical treatment with 0.5% timolol resulted in reduction of IOP in the treated and nontreated eyes. Mean reduction of IOP in the treated eye was 2.5 mm of Hg, a reduction of 16.1%, with maximal reduction of 3.7 mm of Hg. Mean reduction of IOP in the nontreated eye was 1.4 mm of Hg, a reduction of 9.0%. The treated eye had reduced pupil diameter at 30 minutes after treatment, which persisted throughout the 12 hours of the study. Mean reduction of pupil diameter in the treated eye was 2.9 mm, a reduction of 34.1%. In addition, a contralateral effect on pupil diameter was seen in the nontreated eye, with mean reduction of 1.2 mm, a reduction of 14.1%. Topical administration of timolol maleate resulted in reduction of IOP and pupil diameter in treated and contralateral eyes, thus supporting the use of timolol for treatment of glaucoma in dogs. Miosis indicates possible beta-adrenergic inhibition or alpha-adrenergic activation of the sphincter muscle. beta-Adrenergic blockade would then result in miosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2035917

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  8 in total

1.  Comparison of effects of topical levobunolol to a combination of timolol-dorzolamide on intraocular pressure and pulse rate of healthy dogs.

Authors:  M Pugliese; A Scardillo; P P Niutta; A Pugliese
Journal:  Vet Res Commun       Date:  2009-09       Impact factor: 2.459

2.  Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma.

Authors:  Sung Woo Cho; Joon Mo Kim; Ki Ho Park; Chul Young Choi
Journal:  Jpn J Ophthalmol       Date:  2010-11-05       Impact factor: 2.447

3.  Effects of brimonidine timolol fixed combination therapy on anterior ocular segment configuration.

Authors:  Joon Mo Kim; Ki Ho Park; Chan Yun Kim; Hwang Ki Kim; Tae-Woo Kim; Mo Sae Kim
Journal:  Jpn J Ophthalmol       Date:  2011-06-17       Impact factor: 2.447

4.  Safety and efficacy of topically administered netarsudil (Rhopressa™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).

Authors:  Kelly A Leary; Kuan-Ting Lin; Juan P Steibel; Christine D Harman; András M Komáromy
Journal:  Vet Ophthalmol       Date:  2019-12-24       Impact factor: 1.644

5.  Effects of 0.2% brimonidine and 0.2% brimonidine-0.5% timolol on intraocular pressure and pupil size in normal equine eyes.

Authors:  M Von Zup; M Lassaline; P H Kass; P E Miller; S M Thomasy
Journal:  Equine Vet J       Date:  2017-06-05       Impact factor: 2.888

6.  Safety and efficacy of topically administered netarsudil-latanoprost fixed dose combination (FDC; Rocklatan™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).

Authors:  Kelly A Leary; Juan P Steibel; Christine D Harman; Amanda L Anderson; András M Komáromy
Journal:  Vet Ophthalmol       Date:  2021-06-04       Impact factor: 1.644

Review 7.  Looking into the future: Gene and cell therapies for glaucoma.

Authors:  András M Komáromy; Kristin L Koehl; Shin Ae Park
Journal:  Vet Ophthalmol       Date:  2021-01-07       Impact factor: 1.644

8.  Dysregulation of the autonomous nervous system in patients with temporomandibular disorder: a pupillometric study.

Authors:  Annalisa Monaco; Ruggero Cattaneo; Luca Mesin; Irma Ciarrocchi; Fabrizio Sgolastra; Davide Pietropaoli
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.